CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

MenACWY vaccineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug300 ChAdOx1 nCoV-19 + boost Wiki 1.00
drug816 MenACWY vaccine + boost Wiki 1.00
drug302 ChAdox1 n-CoV vaccine low dose Wiki 1.00
drug299 ChAdOx1 nCoV-19 Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

NCT04400838 Coronavirus Biological: ChAdOx1 nCoV-19 Biological: MenACWY vaccine Biological: ChAdOx1 nCoV-19 + boost Biological: MenACWY vaccine + boost Biological: ChAdox1 n-CoV vaccine low dose
MeSH:Coronavirus Infections

Primary Outcomes

Description: Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19

Measure: Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.

Time: 6 months

Description: Occurrence of serious adverse events (SAEs) throughout the study duration.

Measure: Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children

Time: 6 months

Secondary Outcomes

Description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following

Time: 7 days post vaccination

Description: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following

Time: 7 days post vaccination

Description: Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination

Time: 28 days post vaccination

Description: Frequency of participants with clinically significant changes from baseline for safety laboratory measures (haematology and biochemistry blood results)

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests)

Time: 6 months

Description: Occurrence of disease enhancement episodes

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes

Time: 6 months

Description: Number of hospital admissions associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions

Time: 6 months

Description: Number of intensive care unit (ICU) admissions associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19

Time: 6 months

Description: Number of deaths associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths

Time: 6 months

Description: Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates

Time: 6 months

Description: Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates)

Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification

Time: 28 days post vaccination

Description: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 28 post-vaccination

Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion

Time: 28 days post vaccination

Description: Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein

Measure: Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2 and 3 only)

Time: 6 months

Description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): local reactogenicity

Time: 7 days post vaccination

Description: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity

Time: 7 days post vaccination

Description: Occurrence of unsolicited adverse events (AEs) for 28 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)

Time: 28 days post vaccination

Description: Frequency of participants with clinically significant changes from baseline from pre-booster for safety laboratory measures (haematology and biochemistry blood results)

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests)

Time: 6 months

Description: Antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination (seroconversion rates)

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion

Time: 56 days post vaccination

Description: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)

Time: 56 days post vaccination

Other Outcomes

Description: Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus

Measure: Exploratory Immunology by virus neutralising antibody assays

Time: 6 months

Description: Cell analysis by flow cytometry assays

Measure: Exploratory Immunology by flow cytometry

Time: 6 months

Description: Functional antibody assays

Measure: Exploratory Immunology by functional antibody assays

Time: 6 months

Description: Reported by weekly survey to collect information about cases amongst household contacts and friends, contact with the general public, infection control procedures

Measure: Measure exposure to COVID-19

Time: 6 months

No related HPO nodes (Using clinical trials)